Synthesis and SAR optimization of quinazolin-4(3H)-ones as poly(ADP-ribose)polymerase-1 inhibitors.
暂无分享,去创建一个
[1] A. Caflisch,et al. PARP1 ADP-ribosylates lysine residues of the core histone tails , 2010, Nucleic acids research.
[2] Jeremy M. Stark,et al. 53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks , 2010, Cell.
[3] Simon Messner,et al. Molecular mechanism of poly(ADP-ribosyl)ation by PARP1 and identification of lysine residues as ADP-ribose acceptor sites , 2009, Nucleic acids research.
[4] Eric F. Johnson,et al. Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer. , 2009, Journal of medicinal chemistry.
[5] T. Niwa,et al. Discovery and structure-activity relationships of 4-aminoquinazoline derivatives, a novel class of opioid receptor like-1 (ORL1) antagonists. , 2009, Bioorganic & medicinal chemistry.
[6] M. Altmeyer,et al. Identification of lysines 36 and 37 of PARP-2 as targets for acetylation and auto-ADP-ribosylation. , 2008, The international journal of biochemistry & cell biology.
[7] V. Schreiber,et al. Poly(ADP-ribose): novel functions for an old molecule , 2006, Nature Reviews Molecular Cell Biology.
[8] Katharina Dittmar,et al. In silico characterization of the family of PARP-like poly(ADP-ribosyl)transferases (pARTs) , 2005, BMC Genomics.
[9] Thomas Helleday,et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.
[10] Alan Ashworth,et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.
[11] G. Costantino,et al. Docking studies on PARP-1 inhibitors: insights into the role of a binding pocket water molecule. , 2005, Bioorganic & medicinal chemistry.
[12] P. Calsou,et al. Involvement of Poly(ADP-ribose) Polymerase-1 and XRCC1/DNA Ligase III in an Alternative Route for DNA Double-strand Breaks Rejoining* , 2004, Journal of Biological Chemistry.
[13] G. Kéri,et al. Improved, high yield synthesis of 3H-quinazolin-4-ones, the key intermediates of recently developed drugs. , 2004, Current Medicinal Chemistry.
[14] Takayoshi Kinoshita,et al. Rational approaches to discovery of orally active and brain-penetrable quinazolinone inhibitors of poly(ADP-ribose)polymerase. , 2004, Journal of medicinal chemistry.
[15] A. Venkitaraman. Tracing the network connecting brca and fanconi anaemia proteins , 2004, Nature Reviews Cancer.
[16] Jie Zhang,et al. Design and synthesis of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. Part 4: biological evaluation of imidazobenzodiazepines as potent PARP-1 inhibitors for treatment of ischemic injuries. , 2003, Bioorganic & medicinal chemistry.
[17] M. Endres,et al. Protective effects of PJ34, a novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP) in in vitro and in vivo models of stroke. , 2001, International journal of molecular medicine.
[18] K. Murthy,et al. Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation , 2001, Nature Medicine.
[19] N. Curtin,et al. Synthesis and Biological Properties of Benzimidazole Inhibitors of the DNA Repair Enzyme Poly ( ADP-ribose ) Polymerase , 2022 .
[20] N. Curtin,et al. Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP). , 1998, Journal of medicinal chemistry.
[21] M. Threadgill,et al. Synthesis of 3-substituted benzamides and 5-substituted isoquinolin-1(2H)-ones and preliminary evaluation as inhibitors of poly(ADP-ribose)polymerase (PARP). , 1998, Bioorganic & medicinal chemistry.
[22] G. Schulz,et al. The mechanism of the elongation and branching reaction of poly(ADP-ribose) polymerase as derived from crystal structures and mutagenesis. , 1998, Journal of molecular biology.
[23] K. Ueda,et al. Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase. , 1992, The Journal of biological chemistry.
[24] J. Sebolt-Leopold,et al. Dihydroisoquinolinones: the design and synthesis of a new series of potent inhibitors of poly(ADP-ribose) polymerase. , 1991, Anti-cancer drug design.
[25] D. Dexter,et al. Synthesis and biological evaluation of 2-styrylquinazolin-4(3H)-ones, a new class of antimitotic anticancer agents which inhibit tubulin polymerization. , 1990, Journal of medicinal chemistry.
[26] J. Freisheim,et al. Comparison of the biological effects of selected 5,8-dideazafolate analogues with their 2-desamino counterparts. , 1989, Journal of medicinal chemistry.
[27] F. Bellamy,et al. Selective reduction of aromatic nitro compounds with stannous chloride in non acidic and non aqueous medium , 1984 .
[28] D. R. Parrish,et al. (E)-3-(4-Oxo-4H-quinazolin-3-yl)-2-propenoic acids, a new series of antiallergy agents. , 1983, Journal of medicinal chemistry.
[29] Yao-Hua Wu. Arsenicals containing quinoline and quinazoline nuclei , 1952 .
[30] C. Price,et al. 4-(4'-diethylamino-l'-methylbutylamino)-7-chloroquinazoline. , 1946, Journal of the American Chemical Society.